With FDA's REMS Staff Overloaded, Final Guidance Could See Further Delays
Executive Summary
The Risk Evaluation and Mitigation Strategy guidance, which has been under construction by FDA for more than a year, could see further delays before it is finalized
You may also be interested in...
FDA's REMS Stronghold: Industry Sees Need For Alternate Risk Management Plans Beyond Mandatory Programs
As Risk Evaluation and Mitigation Strategies become more and more commonplace, industry is starting to balk at the use of the mandatory programs for every risk management activity
FDA's REMS Stronghold: Industry Sees Need For Alternate Risk Management Plans Beyond Mandatory Programs
As Risk Evaluation and Mitigation Strategies become more and more commonplace, industry is starting to balk at the use of the mandatory programs for every risk management activity
FDA Shouldn't Require Monitoring Of Third Parties In REMS, Industry Says
FDA's requirements for Risk Evaluation and Mitigation Strategies should focus on sponsors' activities and not the behavior of third parties, industry tells the agency in comments on a draft guidance